UCFI

UCFI is not investable in any conventional sense: as of October 1, 2025 Nasdaq suspended trading of the common stock and warrants because China's CSRC told Nasdaq its review of the U.S. listing 'had not been completed,' and per the 10-K the Trading Halt 'remains in effect' with no resolution date. The company only completed its Iron Horse SPAC merger on September 30, 2025 and still owes a CSRC filing for that merger — materials were requested March 19, 2025 and resubmitted, but 'we have not yet obtained the filing notice.' The quoted $5.51 is therefore a stale/illiquid mark on a security you likely cannot buy or sell, and the filing openly warns of outright delisting, shareholder lawsuits, and a drop to OTC with 'greater liquidity and pricing constraints.'

The balance sheet is distressed and cannot absorb this stress. Stockholders' equity is negative at -$4.14M (liabilities/equity of -1.23x is a red flag, not a virtue), cash and equivalents are essentially zero at $454, current assets are just $43.5K against $2.59M of current liabilities (up 200.8%), and retained earnings are a -$4.14M deficit. The MD&A confirms three interest-free promissory notes (to a lender, underwriter D. Boral Capital, and the SPAC sponsor) have all matured, are in default, and the company is 'currently negotiating' extensions — classic going-concern territory.